During recent years, most of the research on the control of sylvatic rabies has concentrated on developing methods of oral vaccination of wild rabies vectors. In order to improve both the safety and the stability of the vaccine used, a recombinant vaccinia virus which expresses the immunizing glycoprotein of rabies virus (VRG) has been developed and extensively tested in the laboratory as well as in the field. From 1989 until 1995, several million VRG vaccine doses have been dispersed in western Europe for vaccination of red foxes. In Europe, the use of VRG has lead to the elimination of sylvatic rabies from large areas, which have consequently been freed from vaccination. This may have consequences on the regulation of pets movements within the whole European Union.